Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophiliaReport as inadecuate




Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia - Download this document for free, or read online. Document in PDF available to download.

BMC Microbiology

, 12:145

First Online: 23 July 2012Received: 13 March 2012Accepted: 23 July 2012DOI: 10.1186-1471-2180-12-145

Cite this article as: Pompilio, A., Crocetta, V., Scocchi, M. et al. BMC Microbiol 2012 12: 145. doi:10.1186-1471-2180-12-145

Abstract

BackgroundTreatment of cystic fibrosis-associated lung infections is hampered by the presence of multi-drug resistant pathogens, many of which are also strong biofilm producers. Antimicrobial peptides, essential components of innate immunity in humans and animals, exhibit relevant in vitro antimicrobial activity although they tend not to select for resistant strains.

ResultsThree α-helical antimicrobial peptides, BMAP-27 and BMAP-28 of bovine origin, and the artificial P199-B peptide were tested, comparatively to Tobramycin, for their in vitro antibacterial and anti-biofilm activity against 15 Staphylococcus aureus, 25 Pseudomonas aeruginosa, and 27 Stenotrophomonas maltophilia strains from cystic fibrosis patients. All assays were carried out in physical-chemical experimental conditions simulating a cystic fibrosis lung. All peptides showed a potent and rapid bactericidal activity against most P. aeruginosa, S. maltophilia and S. aureus strains tested, at levels generally higher than those exhibited by Tobramycin and significantly reduced biofilm formation of all the bacterial species tested, although less effectively than Tobramycin did. On the contrary, the viability-reducing activity of antimicrobial peptides against preformed P. aeruginosa biofilms was comparable to and, in some cases, higher than that showed by Tobramycin.

ConclusionsThe activity shown by α-helical peptides against planktonic and biofilm cells makes them promising -lead compounds- for future development of novel drugs for therapeutic treatment of cystic fibrosis lung disease.

KeywordsCystic fibrosis Antimicrobial peptides Biofilm AbbreviationsCFCystic Fibrosis

AMPsAntimicrobial Peptides

MHAMueller-Hinton agar

SCVsSmall-Colony Variants

CLSIClinical Laboratory Standards Institute

PFGEPulsed-Field Gel Electrophoresis

SCFMSynthetic CF sputum medium

MICMinimum Inhibitory Concentration

MBCMinimum Bactericidal Concentration

CFUColony-Forming Unit

FICIFractionary Inhibitory Concentration Index.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2180-12-145 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Arianna Pompilio - Valentina Crocetta - Marco Scocchi - Stefano Pomponio - Valentina Di Vincenzo - Mario Mardirossian - Giov

Source: https://link.springer.com/







Related documents